Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-39.4
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 July 2025 to 31 March 2026Non-consolidated (standalone)Japanese GAAPNet Sales10,663¥ millionYear on year -39.4%Progress 70.9%
Operating profit3,509¥ millionYear on year -62.4%Progress 80.3%
Ordinary income3,344¥ millionYear on year -64.0%Progress 81.0%
Net income attributable to owners of the parent2,443¥ millionYear on year -63.2%Progress 42.9%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥23.36
Financial position at period-end
Total assets41,447¥ million
of which net assets 16,308 ¥ millionEquity ratio 39.3%vs. prior year-end -8.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥15,048 million (YoY -19.2%)
Operating profit¥4,368 million (YoY -47.1%)
Ordinary income¥4,127 million (YoY -49.8%)
Net income¥5,692 million (YoY -9.9%)
Annual Dividend Forecast¥28 → ¥28（0.0%）
Factors Behind Changes in Business Performance
In the year-earlier period, wholesalers built up their inventories of antigen test kits in the general market. As a result, market inventories were being worked down during the current period, and the scale of the COVID-19 outbreak was smaller than in the year-earlier period.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥1,775 thousand, Government subsidies ¥414,006 thousand, Gain on reversal of subscription rights to shares ¥2 thousand / Extraordinary loss Loss on sale of fixed assets ¥0 thousand, Loss on Disposal of Fixed Assets ¥0 thousand, Impairment Loss on Investment Securities ¥11,256 thousand, Impairment Losses on Shares of Affiliates ¥241,404 thousand
Depreciation and amortization¥727,030 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingEvent No / Subject person Not disclosed
Issued Shares at Period-End106,454,551 Shares
Treasury Shares at Period-End0 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Net Sales | ¥10,663 million (YoY -39.4%) |
| Operating profit | ¥3,509 million (YoY -62.4%) |
| Ordinary income | ¥3,344 million (YoY -64.0%) |
| Profit attributable to owners of the parent | ¥2,443 million (YoY -63.2%) |
| Net income per share | ¥23.36 |
| Equity ratio | End of the current fiscal period 39.3 / End of previous period 47.7 |
| Total assets | ¥41,447 million |
| Net assets | ¥16,308 million |
| Full-year earnings forecast | Net Sales ¥15,048 million (YoY -19.2%) / Operating profit ¥4,368 million (YoY -47.1%) / Ordinary income ¥4,127 million (YoY -49.8%) / Net income ¥5,692 million (YoY -9.9%) |
| Annual Dividend Forecast | ¥28 → ¥28（0.0%） |
| Depreciation and amortization | ¥727,030 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1,775 thousand, Government subsidies ¥414,006 thousand, Gain on reversal of subscription rights to shares ¥2 thousand / Extraordinary loss Loss on sale of fixed assets ¥0 thousand, Loss on Disposal of Fixed Assets ¥0 thousand, Impairment Loss on Investment Securities ¥11,256 thousand, Impairment Losses on Shares of Affiliates ¥241,404 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Event No / Subject person Not disclosed |
| Issued Shares at Period-End | 106,454,551 Shares |
| Treasury Shares at Period-End | 0 Shares |
| Factors Behind Changes in Business Performance | In the year-earlier period, wholesalers built up their inventories of antigen test kits in the general market. As a result, market inventories were being worked down during the current period, and the scale of the COVID-19 outbreak was smaller than in the year-earlier period. |
Items this document does not state (15)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossChanges in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the year-earlier period, wholesalers built up their inventories of antigen test kits in the general market. As a result, market inventories were being worked down during the current period. In addition, the scale of the COVID-19 outbreak was smaller than in the year-earlier period.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.